IVVD

Invivyd, Inc.

A biopharmaceutical company making monoclonal antibody medicines for viral diseases, Invivyd's only commercial product is PEMGARDA (pemivibart), a preventive antibody given to certain immunocompromised adults and teens at risk of COVID-19. It was founded in 2020 as Adagio Therapeutics, a spin-out of the antibody-discovery firm Adimab, and renamed Invivyd in 2022. The name hints at its mission of building antibodies that outpace fast-mutating viruses.

Recent Activity

Show $

2025Q3

1 buy

Maverick CapitalADD

+8.74M shares(+85.5%)

Maverick CapitalADD

+8.74M shares(+85.5%)

2025Q2

1 sell

Maverick CapitalTRIM

-729.5K shares(-6.7%)

Maverick CapitalTRIM

-729.5K shares(-6.7%)

2025Q1

1 sell

Maverick CapitalTRIM

-807.2K shares(-6.9%)

Maverick CapitalTRIM

-807.2K shares(-6.9%)

Loading more activity...